Answers are grounded in this paper and cite their sources.
The FDA has required a new warning in the label of the oral selective neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah) about the risk of hepatoxicity.1,2 The label of fezolinetant, which was approved by the FDA in 2023 for treatment of moderate to severe vasomotor symptoms due to menopause, already contained a warning about hepatic transaminase elevations associated with use of the drug.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: